Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-dose chemo feasible for older, frail patients with advanced gastroesophageal cancer

Publish date:: May 17, 2019

Key clinical point: The lowest dose of oxaliplatin and capecitabine proved noninferior to two higher doses in a study of older and frail patients with advanced gastroesophageal cancer.

Major finding: Noninferiority for progression-free survival was confirmed for the lowest dose, compared with the highest dose (hazard ratio, 1.10).

Study details: A phase 3 trial of 514 older and/or frail patients with advanced gastroesophageal cancer.

Disclosures: The trial was funded by Cancer Research UK and sponsored by the University of Leeds. The lead author reported relationships with Eisai, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, and Novartis.

Citation:

Hall PS et al. ASCO 2019, Abstract 4006.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,